The "Oncopro 350 Gene TMB and MSI Profile Test" is a sophisticated diagnostic tool available at DNA Labs UAE, designed to provide comprehensive insights into the genetic profile of a patient's cancer. Priced at 15,210 AED, this test screens for mutations across 350 cancer-related genes, alongside assessing Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) status. These metrics are crucial for understanding the behavior of cancer at a molecular level, guiding personalized treatment strategies. The TMB evaluation helps in determining the likelihood of response to immunotherapy, while MSI status can indicate susceptibility to certain types of cancer treatments. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a critical step towards tailored cancer care, offering hope for more effective and targeted therapy options.
The Oncopro Tumor Mutation Burden (TMB) Test is a cutting-edge diagnostic tool available at DNA Labs UAE, designed to assess the number of mutations within a tumor's DNA. This test plays a crucial role in the field of oncology, as the Tumor Mutation Burden is a biomarker that can predict how well a patient might respond to certain immunotherapies. By evaluating the quantity of mutations, the test can help oncologists tailor more effective and personalized treatment plans for patients with various types of cancer.
The test involves a comprehensive analysis of the tumor tissue to quantify the mutation burden, providing valuable insights into the tumor's behavior and its potential response to treatment. This information is pivotal for determining the suitability of immunotherapy, which works by empowering the patient's immune system to recognize and combat cancer cells more effectively.
Administered at DNA Labs UAE, a facility known for its advanced diagnostic technologies and precision medicine, the Oncopro TMB Test is available for a cost of 14,040 AED. This investment can be a crucial step for patients seeking personalized cancer therapy options, offering a beacon of hope for improved treatment outcomes by leveraging the power of genetic insights to combat cancer.
The "HLA Pre-Transplant Workup Sensitized Recipient Panel 4 Test" is a specialized diagnostic procedure conducted at DNA Labs UAE, designed to evaluate potential transplant recipients for sensitization to human leukocyte antigens (HLA). This test is crucial for identifying individuals who have developed antibodies against HLA, which can significantly impact the success rate of organ transplants. Sensitization can occur due to previous transplants, blood transfusions, or pregnancies, making it essential to assess the compatibility between donor and recipient to minimize the risk of organ rejection.
The test involves a comprehensive analysis of the recipient's immune response to various HLA antigens, providing invaluable information for the medical team to make informed decisions regarding transplantation strategies. The cost of this detailed and critical assessment is 14,040 AED, reflecting the sophisticated technology and expertise required to conduct the test and interpret its results. Conducted at DNA Labs UAE, a facility known for its state-of-the-art technology and highly qualified professionals, this test is a vital step in the pre-transplant evaluation process, ensuring the highest possible success rates for organ transplants by identifying and addressing potential challenges related to HLA sensitization.
The Oncomine Comprehensive Assay Test, available at DNA Labs UAE for a cost of 13,740 AED, is a cutting-edge, next-generation sequencing (NGS) test designed to detect genetic mutations and alterations in cancer patients. This comprehensive assay is capable of analyzing both DNA and RNA from solid tumors to identify a wide array of genetic variants across multiple cancer types. By pinpointing specific mutations, the Oncomine Comprehensive Assay aids oncologists in making informed decisions about personalized treatment options, including targeted therapies and clinical trial eligibility. Conducted in a state-of-the-art facility, DNA Labs UAE ensures precise and reliable results, supporting the advancement of precision medicine in cancer care.
Carrier screening tests are genetic tests designed to determine whether an individual is a carrier of specific genetic disorders. These tests are particularly important for couples planning to have children, as they can help identify the risk of passing on genetic conditions to their offspring. The carrier screening test at DNA Labs UAE is comprehensive, offering insights into a wide array of genetic disorders that could potentially affect future generations.
The cost of the carrier screening test at DNA Labs UAE is 11,400 AED. This investment allows prospective parents to make informed decisions about their family planning, armed with knowledge about their genetic makeup and potential risks. The testing process involves collecting a small sample of DNA, typically through a blood draw or a cheek swab, which is then analyzed in the lab for genetic markers associated with various inherited conditions.
DNA Labs UAE utilizes advanced genetic testing technologies to provide accurate and reliable results. The screening covers a broad spectrum of genetic disorders, ensuring that individuals have a comprehensive understanding of their carrier status. With this information, couples can seek genetic counseling and consider their options for family planning with greater confidence and peace of mind.
The MI Molecular Intelligence Profile Test, available at DNA Labs UAE, represents a cutting-edge diagnostic approach that leverages advanced molecular analysis to uncover detailed insights into an individual's genetic makeup. Priced at 117,000 AED, this comprehensive test is designed to identify genetic predispositions to various health conditions, potential responses to certain medications, and overall genetic health risks. By analyzing an individual's DNA, the MI Molecular Intelligence Profile Test can provide personalized recommendations for lifestyle adjustments, dietary changes, and preventive measures to optimize health and well-being. DNA Labs UAE, known for its state-of-the-art facilities and expert team, ensures a thorough and accurate analysis, making the MI Molecular Intelligence Profile Test a valuable tool for those seeking to understand their genetic profile and take proactive steps towards personalized healthcare.
The MI Molecular Intelligence Tumor Seek Test is an advanced diagnostic tool designed to identify the genetic alterations in a patient's tumor. By analyzing the DNA and RNA of cancer cells, this test provides a comprehensive molecular profile of the tumor, which can guide personalized treatment strategies. It aims to match patients with targeted therapies and clinical trials that are most likely to be effective for their specific cancer type, based on the unique genetic makeup of their tumor.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics and research, the test leverages cutting-edge sequencing technologies to decode the complex biology of cancer. The cost of the MI Molecular Intelligence Tumor Seek Test is 93,600 AED, reflecting the extensive analysis and detailed insights it offers into the molecular drivers of an individual's cancer. This investment can be crucial for patients seeking to optimize their treatment options and improve their outcomes by targeting the root genetic causes of their disease.
The Genome Signature HRD (Homologous Recombination Deficiency) Test is a cutting-edge diagnostic tool available at DNA Labs UAE, designed to evaluate the inability of cancer cells to repair double-stranded DNA breaks. This test plays a crucial role in the field of personalized medicine, especially in the context of cancer treatment, by identifying patients who are likely to benefit from specific therapies, such as PARP inhibitors. The test examines the genome for signatures that indicate a deficiency in homologous recombination, a critical pathway for DNA repair. By doing so, it helps in predicting the responsiveness of certain cancers, including breast, ovarian, and prostate cancers, to specific treatments, thereby allowing for more targeted and effective therapeutic approaches. The cost of the Genome Signature HRD Test at DNA Labs UAE is 54,000 AED, reflecting the sophisticated technology and expertise required to conduct this specialized diagnostic procedure.
The NGS TP53 Mutation Analysis Test, available at DNA Labs UAE for a cost of 42,000 AED, is a sophisticated genetic testing procedure designed to identify mutations in the TP53 gene. This gene plays a crucial role in regulating cell division and preventing the development of tumors, making its analysis vital for understanding individual cancer risks and for the diagnosis of certain genetic disorders, such as Li-Fraumeni syndrome. Utilizing Next-Generation Sequencing (NGS) technology, the test offers a comprehensive examination of the TP53 gene, allowing for the detection of both known and novel mutations with high precision and accuracy. The results from this test can provide essential information for personalized treatment planning, including decisions regarding surveillance, surgery, chemotherapy, or radiation therapy, enhancing the potential for positive patient outcomes. Conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services, the NGS TP53 Mutation Analysis Test represents a significant advancement in the field of personalized medicine and genetic diagnostics.
The Oncomine Comprehensive Plus Panel Test is a cutting-edge genetic test designed to provide a comprehensive analysis of cancer-related genes. This test, performed by DNA Labs UAE, is aimed at identifying genetic mutations and alterations in a wide array of genes associated with different types of cancer. With a cost of 39,000 AED, it offers an extensive assessment that helps in guiding personalized treatment plans for cancer patients.
The test utilizes next-generation sequencing (NGS) technology to examine a broad panel of genes for mutations that could influence a patient's response to certain cancer therapies, making it an invaluable tool in the realm of precision medicine. By pinpointing specific genetic mutations, healthcare providers can tailor treatments to the individual's genetic profile, potentially improving outcomes and minimizing unnecessary side effects.
The Oncomine Comprehensive Plus Panel Test is particularly useful for patients with advanced or difficult-to-treat cancers, where conventional treatment options may have been exhausted or are deemed less effective. The insights gained from this test can lead to the identification of targeted therapies and clinical trial opportunities that are most likely to benefit the patient based on their unique genetic makeup.
DNA Labs UAE, known for its state-of-the-art facilities and expertise in genetic testing, ensures that the test is conducted with the highest standards of accuracy and reliability. Their team of specialized geneticists and clinicians work closely with patients and healthcare providers to interpret the results and integrate them into the patient's care plan.
In summary, the Oncomine Comprehensive Plus Panel Test offered by DNA Labs UAE is a significant advancement in cancer care, providing a deeper understanding of the genetic underpinnings of an individual's cancer and opening up personalized treatment avenues. With its comprehensive approach and the high cost reflective of its extensive analysis, it represents a crucial step forward in the fight against cancer.
